ArticleDiabetology & metabolic syndrome2025
Causal association between immunoglobulin G N-glycosylation patterns and diabetic complications: two-sample mendelian randomization.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
backgroundTo elucidate the correlation between immunoglobulin G (IgG) N-glycosylation patterns (IGPs) and diabetes complications, including diabetic nephropathy (DN), diabetic retinopathy (DR) and diabetic maculopathy (DM). We performed a two-sample Mendelian randomization (MR) study.
methodsWe obtained genome-wide association studies (GWAS) summary statistics related to 77 IGPs and diabetic complications from the MRC Human Genetics Unit and the FinnGen consortium. In our two-sample MR, genetic variants associated with IGPs were used to estimate correlations. The inverse-variance weighted (IVW) method was used as the primary analysis. Various complementary methods, including MR-Egger, weighted median (WM), and weighted mode were implemented to detect the causal relationship. Sensitivity analyses including MR-PRESSO, MR-Egger, Cochran's Q and leave-one-out methods were used to validate the robustness of the results.
resultsAfter MR-PRESSO outlier correction and a stringent False Discovery Rate (FDR) correction, a significant causal association was identified: higher levels of IGP48 were robustly associated with an increased risk of diabetic maculopathy (DM) (OR: 1.21, 95% CI: 1.09-1.35, P = 0.001, FDR = 0.004). Additionally, several other nominal associations (P < 0.05) were observed that did not withstand FDR correction but suggest areas for future investigation. These included protective associations with DM for IGP18 (OR: 0.86, P = 0.033) and IGP35 (OR: 0.90, P = 0.015), and risk associations for IGP23 (OR: 1.19, P = 0.028) and IGP28 (OR: 1.17, P = 0.038). For diabetic retinopathy (DR), a nominal protective association was found for IGP35 (OR: 0.94, P = 0.026) and a risk association for IGP48 (OR: 1.07, P = 0.042). Sensitivity analyses detected no significant horizontal pleiotropy, and the results were stable.
conclusionOur study provides robust genetic evidence identifying IGP48 as a causal risk factor for DM. Other nominal associations with DM and DR require further validation. IGP48 emerges as a promising biomarker and therapeutic target for DM, warranting further research into its underlying mechanisms and clinical utility.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.